Welcome to SIGA Technologies
At SIGA, we specialize in developing therapeutic solutions for some of the most lethal disease-causing pathogens – smallpox, Ebola, dengue, Lassa fever and other dangerous viruses. Our business is to discover, develop, manufacture and successfully commercialize drugs to prevent and treat these high-priority threats.
Our Lead Product, ST-246®
Our first commercial product, ST-246® (Tecovirimat), is a novel drug under development for the treatment of smallpox – one of the deadliest diseases that mankind has ever faced and still a potential bioterrorism and biowarfare threat. Sales of this drug have transformed our company to a commercial-stage venture and will support continuing development of our other drug candidates.
Questions and Answers Concerning ST-246® Procurement Contract - Download Here
Our most important contract is our contract with the U.S. government to produce and sell ST 246®, our smallpox antiviral, to the U.S. Strategic National Stockpile. The link above will take you to a statement by our Chairman and Chief Executive Officer, Dr. Eric A. Rose, which explains the rationale behind this contract. Dr. Rose explains the need for ST-246®, its value and how the acquisition process worked, in accordance with all governing standards. We urge our shareholders and all other interested parties to download this statement.